On July 13, the U.S. Food and Drug Administration (FDA) approved
- Rexulti (brexpiprazole) to treat adults with schizophrenia and as an add-on treatment to an antidepressant medication to treat adults with major depressive disorder. Read more.
- Iressa (gefitinib) for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors harbor specific types of epidermal growth factor receptor gene mutations, as detected by an FDA-approved test. Read more.